There was a lack of data on the therapy of chronic active T cell-mediated rejection (CA-TCMR), and no therapeutical treatments for CA-TCMR have been developed. For a study, researchers sought to determine the results and effects of therapy on pathological and clinical findings in CA-TCMR patients.
The study included 37 CA-TCMR patients who had kidney transplants at our facility between January 2018 and December 2020. Patients will be monitored until October 20, 2021.
About 32 of the 37 patients received treatment. During the study period, two patients (5%) died, and five had allograft loss (13% ). Indication biopsy, greater spot urine protein/creatinine ratio, and Banff ci/ct scores were all risk variables for allograft loss, according to a univariate Cox proportional (UPCR) hazards model. Around 23 of the treated individuals had follow-up biopsies. The Baff scores for “ti”, “i-IFTA”, “t”, and “t-IFTA” improved significantly following therapy, according to the Wilcoxon signed-rank test. Pathology revealed that 13 (57%) of patients who had a follow-up biopsy improved to “no indication of rejection” or “borderline alteration.” Assuming that improvement in pathology to “borderline change” or “no indication of rejection” on follow-up biopsy indicated treatment response, the multivariate logistic analysis revealed that reduced UPCR was a predictor of treatment success. There was no discernible impact of therapy kind.
The data suggested that therapy may ameliorate the pathological findings in CA-TCMR.